Trogenix announces publication of breakthrough pre-clinical data in Nature demonstrating complete tumour eradication and durable protection in aggressive brain cancer model
Trogenix’s proprietary Synthetic Super-Enhancers achieved complete tumour eradication in 83% of treated glioblastoma cases with no toxicity over 11 months and provided durable protection against tumour recurrence.
Synthetic Super-Enhancers delivered by AAV vectors to SOX2/ SOX9-driven glioblastoma stem cells caused rapid tumour regression and complete clearance in 83% of cases, with no toxicity or recurrence over an 11‑month observation period, demonstrating durable immune‑mediated protection.
This pre‑clinical proof‑of‑concept indicates that a single‑dose gene‑therapy approach can **potentially cure glioblastoma**, a highly lethal brain cancer, by combining targeted tumour killing with long‑lasting immune activation while sparing normal brain tissue.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.